Cargando…

The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma

T helper type 2 cells (Th2 cells) and group 2 innate lymphoid cells (ILC2s) play an important role in the pathophysiology of asthma, including airway eosinophilic inflammation. ILC2s are activated by epithelial-derived cytokines [interleukin-25 (IL-25), IL-33, and thymic stromal lymphopoietin (TSLP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuyama, Takahiro, Matsuyama, Hiromi, Dotake, Yoichi, Takagi, Koichi, Machida, Kentaro, Inoue, Hiromasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327784/
https://www.ncbi.nlm.nih.gov/pubmed/35911708
http://dx.doi.org/10.3389/fimmu.2022.930862
_version_ 1784757575598735360
author Matsuyama, Takahiro
Matsuyama, Hiromi
Dotake, Yoichi
Takagi, Koichi
Machida, Kentaro
Inoue, Hiromasa
author_facet Matsuyama, Takahiro
Matsuyama, Hiromi
Dotake, Yoichi
Takagi, Koichi
Machida, Kentaro
Inoue, Hiromasa
author_sort Matsuyama, Takahiro
collection PubMed
description T helper type 2 cells (Th2 cells) and group 2 innate lymphoid cells (ILC2s) play an important role in the pathophysiology of asthma, including airway eosinophilic inflammation. ILC2s are activated by epithelial-derived cytokines [interleukin-25 (IL-25), IL-33, and thymic stromal lymphopoietin (TSLP)] from airway epithelial cells, leading to the release of high amounts of type 2 cytokines, such as IL-5 and IL-13. ILC2s induce airway inflammation in an antigen-independent manner, and ILC2s are considered to be involved in the pathogenesis of asthma exacerbation. Furthermore, ILC2 activation might also confer steroid resistance. Many recent studies in humans and mice are increasingly demonstrating that the function of ILC2s is regulated not just by epithelial-derived cytokines but by a variety of cytokines and mediators derived from innate immune cells. Furthermore, the biologics targeting these cytokines and/or their receptors have been shown to reduce asthma exacerbations and improve lung function and quality of life in asthmatics. This article reviews the current treatment landscape for type 2 airway inflammation in asthma and discusses the therapeutic potential for targeting ILC2s.
format Online
Article
Text
id pubmed-9327784
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93277842022-07-28 The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma Matsuyama, Takahiro Matsuyama, Hiromi Dotake, Yoichi Takagi, Koichi Machida, Kentaro Inoue, Hiromasa Front Immunol Immunology T helper type 2 cells (Th2 cells) and group 2 innate lymphoid cells (ILC2s) play an important role in the pathophysiology of asthma, including airway eosinophilic inflammation. ILC2s are activated by epithelial-derived cytokines [interleukin-25 (IL-25), IL-33, and thymic stromal lymphopoietin (TSLP)] from airway epithelial cells, leading to the release of high amounts of type 2 cytokines, such as IL-5 and IL-13. ILC2s induce airway inflammation in an antigen-independent manner, and ILC2s are considered to be involved in the pathogenesis of asthma exacerbation. Furthermore, ILC2 activation might also confer steroid resistance. Many recent studies in humans and mice are increasingly demonstrating that the function of ILC2s is regulated not just by epithelial-derived cytokines but by a variety of cytokines and mediators derived from innate immune cells. Furthermore, the biologics targeting these cytokines and/or their receptors have been shown to reduce asthma exacerbations and improve lung function and quality of life in asthmatics. This article reviews the current treatment landscape for type 2 airway inflammation in asthma and discusses the therapeutic potential for targeting ILC2s. Frontiers Media S.A. 2022-07-13 /pmc/articles/PMC9327784/ /pubmed/35911708 http://dx.doi.org/10.3389/fimmu.2022.930862 Text en Copyright © 2022 Matsuyama, Matsuyama, Dotake, Takagi, Machida and Inoue https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Matsuyama, Takahiro
Matsuyama, Hiromi
Dotake, Yoichi
Takagi, Koichi
Machida, Kentaro
Inoue, Hiromasa
The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma
title The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma
title_full The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma
title_fullStr The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma
title_full_unstemmed The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma
title_short The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma
title_sort therapeutic potential for targeting group 2 innate lymphoid cells in asthma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327784/
https://www.ncbi.nlm.nih.gov/pubmed/35911708
http://dx.doi.org/10.3389/fimmu.2022.930862
work_keys_str_mv AT matsuyamatakahiro thetherapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT matsuyamahiromi thetherapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT dotakeyoichi thetherapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT takagikoichi thetherapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT machidakentaro thetherapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT inouehiromasa thetherapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT matsuyamatakahiro therapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT matsuyamahiromi therapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT dotakeyoichi therapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT takagikoichi therapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT machidakentaro therapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma
AT inouehiromasa therapeuticpotentialfortargetinggroup2innatelymphoidcellsinasthma